Welcome to the Second 2020 Issue of The CLL Society Tribune
Dear Friends and Supporters of the CLL Society,
We are watching and waiting… now more than ever… and we want February 2020 back.
In this issue of the CLL Society Tribune, we share with you the viewpoints of writers from our CLL community who, just like you, were challenged by the sudden appearance of COVID-19, have had their mobility unexpectedly restricted, are cautious of the threat of infection at the door, are sheltering in place, miss their loved ones, long for a reliable directive from credible institutions to develop survival strategies for us, pray for a vaccine or an effective level of herd immunity… and are watching and waiting… now more than ever… for the “all clear”.
However, all of our writers are strong, articulate and coping. We hope that you find some delight in their spunk and resilience. We thank them for speaking with such lucidity.
This Tribune is focused on new concepts in immunotherapy as Dr. Koffman contributes explanatory articles on “What is immunotherapy?” and on bi-specific antibodies. Under Conference Coverage we further expand the focus on bi-specific antibodies as we feature the CLL Society’s ASH 2019 interview in which Drs. John Pagel and Stephen Schuster discuss the latest research on this topic. Did You Know outlines the Byzantine logic behind the nomenclature for monoclonal antibodies.
Additionally, our CLL expert Dr. Rick Furman, Chief Medical Officer Dr. Brian Koffman, Laboratory Scientist Dr. Susan Leclair, and Pharmacist Tom Henry have been hard at work, possibly breaking a record here by generously answering over 100 patient questions. Was one of these a burning question for you?
We are grateful to Therese Conlin for proofreading this Tribune.
We all want February 2020 back, but in the meantime, stay strong and wash your hands.
The CLL Society is invested in your long life.
Please invest in the long life of the CLL Society by supporting our work.
We are all in this together.
Patty Koffman, Co-Founder & Communications Director
In this edition of the CLL Society Tribune, instead of including an Ask & Tell Survey, we are asking for your feedback on the Tribune publication. How can we improve the quarterly newsletter? What sections are most popular with our readers? We hope that you enjoy the CLL Society Tribune and we want to hear your feedback. Please take a moment to complete this brief evaluation.. … Read more!
Immune therapy is a big piece of solving the puzzle of a CLL cure, and I believe bispecific antibodies may be a helpful puzzle piece. … Read more
ASH 2019: Dr. Schuster on Mosunetuzumab, a Bispecific Antibody in Poor Prognosis Non-Hodgkin Lymphoma Patients
By Brian Koffman, MDCM
At ASH 2019 in Orlando, Dr. John Pagel interviewed Dr. Stephen Schuster about the powerful results in a phase 1 trial of mosunetuzumab, a bispecific antibody. … Watch The Interview
By Richard Furman, MD
Dr. Richard Furman of Weill-Cornell Medical College answers readers’ questions submitted to the CLL Society…Read more
Thomas E Henry III, MBA, RPh, CPh from Burlington Consulting Associates answers readers’ pharmacy questions submitted to the CLL Society…Read more
Susan J. Leclair from University of Massachusetts Dartmouth answers readers’ lab scientist questions submitted to the CLL Society…Read more
The CLL Society Tribune is made possible in part by grant support from AbbVie, Genentech, and Astra Zeneca
The CLL Society does not provide medical advice or endorsements. Unless explicitly stated otherwise, all content in the CLL Tribune is the opinion or information of its author, not the CLL Society. This newsletter is for reference and educational purposes only and is not a substitute for medical advice. We do not guarantee the accuracy of any of the materials. Always contact your own doctor or other professional healthcare provider if you have any questions concerning your or your family’s health. Everyone’s circumstances are different.